Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Ovid Therapeutics Inc. (OVID)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
1.8400-0.0500 (-2.65%)
At close: 04:00PM EDT
1.8200 -0.02 (-1.09%)
After hours: 06:24PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.8900
Open1.8600
Bid1.8100 x 800
Ask1.9500 x 1400
Day's Range1.8300 - 1.8800
52 Week Range1.6500 - 3.7800
Volume189,356
Avg. Volume92,109
Market Cap125.29M
Beta (5Y Monthly)1.30
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Ovid Therapeutics to Present at the Ladenburg Thalmann 2022 Healthcare Conference

    NEW YORK, Sept. 27, 2022 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by brain disorders, today announced that management will present at the Ladenburg Thalmann 2022 Healthcare Conference in New York, New York on Thursday, September 29, 2022, at 9:00 a.m. ET. A live webcast of the presentation can be accessed through the Events & Presentations sectio

  • GlobeNewswire

    Ovid Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference

    NEW YORK, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by brain disorders, today announced that management will present at the H.C. Wainwright 24th Annual Global Investment Conference in New York, New York on Monday, September 12, 2022, at 12:00 p.m. ET. A live webcast of the presentation can be accessed through the Events & Presentati

  • GlobeNewswire

    Ovid Therapeutics Reports Second Quarter 2022 Financial Results and Corporate Highlights

    Anticipates filing an Investigational New Drug application for OV329, a potent GABA-aminotransferase inhibitor, and initiating a Phase 1 trial in the second half of 2022 Presented preclinical data from six animal models reinforcing the seizure-reducing potential of OV329 at two leading epilepsy research meetings Ended the second quarter 2022 with cash, cash equivalents and marketable securities of $152.4 million, expected to support the advancement of its epilepsy pipeline into 2025 NEW YORK, Au

Advertisement
Advertisement